Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease

NCT05026177 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

1125

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision

Conditions

Alzheimer Disease

Interventions

DRUG: Simufilam
DRUG: Placebo

Sponsor

Cassava Sciences, Inc.

Collaborators

[object Object]